DOCSLIB.ORG

Neurotoxicity in the Brain

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neurotoxicity in the Brain 4/7/20 Normal tryptophan metabolism with low levels of inflammatory stressors 46 • Quinolate path (verses melatonin path)- triggered by inflammation • Mitigation of pathway- estradiol, niacin, mitigating of inflammation • Branch chain amino acids can prevent tryptophan from getting into the brain 47 Neurotoxicity in the Brain Treatment Considerations: • Controlled release* 5HTP (100-400mg in divided doses daily • Optimize B6 levels (P5P best) 50-100mg/day • Optimize methyl folate 5-10mg/day • Optimize methyl B12 (1-2mg/day) • Consider BCAA *Some evidence suggest short acting 5HTP can cause cortisol spike 48 1 4/7/20 Natural Anti-inflammatories and Dosing: • Curcumin 750-1500mg/ d • Quercetin 1500-3000 mg/d • Alpha lipoic acid (ALA)- 300- 1800 mg/d • N-acetylcysteine (NAC) 500-3000 mg/d • Essential Fatty Acids- EPA/DHA 1gram-4gram/d • Bosweillia- 400-1200mg/d • Niacinamide 2,000-5,000 mg/d • Palmitoylethanolamide (PEA) 350mg 1-2x daily 49 Medication Tools for Glutamate Modulation Glutamate antagonists for neurological ecotoxicity (ASD, ADD, Parkinson, Alzheimer dementia, PANs, Tics, GAD mutations) 1. Amantadine- 50-200mg QD-BID with “holidays” ; Antiviral, NMDA receptor antagonist 2. Osmolex- ER Amantadine new on the market; ER TAB: 129 mg, 193 mg, 258 mg 3. Namenda- NMDA receptor antagonist; start with 2.5mg QD-BID, can move up to 5mg BID 4. Nuedexta (dextromethorphan/quinidine)- PBA (1/2-1 cap QD-BID) Specialty compounding can help with accessibility and extreme savings if insurance does not cover. ***Warning with compounding pharmacies*** 50 Supplement Tools, Cont. 1. Palmitoylethanolamide(PEA) ; 350mg QD- BID; pain, inflammation, anything that can benefit from NSAID. Consider loading dose of 700mg BID X 2-3 weeks. 2. Cannabidiol (CBD)- 10-50mg up to TID PRN 3. Inositol- Myo (up to 18grams in OCD found effective)- D- Chiro for PCOS and metabolic and autophagy pathologies; 500mg QD-BID 4. GABA- 100-400mg up to BID 5. L-Theanine- 400mg up to QID 6. Magnesium- forms preferred are threonate or glycinate; 80 grams of elemental weight or up to 1 gram up to BID; toxicity is RARE 51 2 4/7/20 52 53 54 3 4/7/20 55 56 57 4 4/7/20 58 59 *Check routine serum studies with iron, zinc, and D supplementation 60 5 4/7/20 Functional Preferences with Thyroid Medications • NP Thyroid • Nature Thyroid • Armour Thyroid • Compounded Thyroid* Caution • Recheck Q6-12 weeks 61 Heavy Metal Toxicity & Fatigue How do we become toxic? Total toxic exposure -Ability to biotransform -Ability to excrete toxins =TOTAL TOXIC LOAD 62 Toxic Metals Sources: top 3 metals include lead, arsenic, mercury Sources: dental implants, water, old construction, guns, fish, rice Effect: can cause burden to mitochondria and impairs autophagy 63 6 4/7/20 Current Toxic Exposures Vs Net Toxic Exposures Current= exposure happened within the last 1-3 months Detected in blood and urine Net= Exposure over lifetime Detected via: Provoked urine (with DMSA) Hair metals Urine porphyrin Signed consent when using RX chelation agents, to provoke, and/or to treat. 64 Topical DMSA/ALA • 5 mg/kg 3 x daily, applied for 3 days on/11 days off. • Benefits- bypasses gut absorption and may have less yeast symptoms/less side effects. • Risks- possible depletion of essential minerals which need to be monitored and repleted. • Labs recommended- Hair metal, urine, porphyrin, or blood test. Basic labs recommended to monitor liver and kidney function throughout therapy in addition to basic nutrients. • Support- Vitamin C, vitamin E, magnesium, zinc, milk thistle, NAC, and adrenal cortex extract. 65 Ethylenediaminetetraacetic Acid (EDTA) • EDTA 500 -750 mg suppository, 1-3 x per week. • Benefits- efficient for lead and mercury removal. Typically less GI side effects or flares in yeast. • Risks- EDTA can be dangerous when it is used while the patient has a current exposure to mercury. Once the mercury is bound in the body, it is very unlikely that EDTA would make it more toxic. • Labs recommended-Hair metal, urine, porphyrin, or blood test. Basic labs recommended to monitor liver and kidney function throughout therapy in addition to basic nutrients. • Support- vitamin C, vitamin E, magnesium, zinc, milk thistle, iron, NAC, and adrenal cortex extract. 66 7 4/7/20 Glutathione: Best IV Rectal 600mg daily Oral 600mg BID-TID NAC precursor 67 Mold/Mycotoxin Toxicity Testing: Mycotoxin testing through Great Plain Labs, Richie Shoemaker protocols, serum positive candida (IgM+). Known exposures in home by certified mold specialist. FIRST REMOVE PATIENT FROM SOURCE OF EXPOSURE Treatment: 6 weeks minimum- average 3 months • Nystatin 500-1M TID OR cholestyramine ½-1 packet BID-TID (magnesium to help mitigate constipation SE, watch lipids) • BEG spray x 3 weeks (compound contains mupirocin + EDTA + gentamicin; breaks up biofilm and MARCONs • Oral glutathione - 600mg BID-TID • NAC or glutathione nebulized • Binders for those who herx (bentonite clay, charcoal timed after antifungal) • Infrared sauna therapy, sweating • Retest biomarkers to ensure treatment efficacy esp if sx have not resolved 68 Biomarkers to Consider Gut: Parasitology X 3, PCR Cx, yeast/candida, food allergies (IgE, IgG, IgA) Thyroid: TSH, Free T3, Free T4, AB/TPO Nutrients: Iron/IBC, Vitamin D, MMA (B12), folate, ferritin, zinc, selenium, iodine, CoQ10, magnesium, carnitine, B1, B2 Metabolic/Inflammatory: A1C, insulin, HsCRP, homocysteine, GGT, CMP, cholesterol, organic acids Toxic: Lead, arsenic, mercury, mold (Mycotoxins), environmental allergies Infectious: EBV, strep (ASO, DNASE), candida, lyme 69 8 4/7/20 70 Mindfulness Meditation Mindfulness meditation often uses either slow, intentional breathing or imagery to help to focus the thoughts. Benefits include: • Reduced insomnia • Deeper sleep • Fewer episodes of wakefulness during the night • Improved mood and resilience • Greater daytime energy • Less anxiety 71 Simplified Approach to Fatigue Management Remove mediating stressors: Mitochondrial and inflammatory stressors Allergic stressors (food, environment) Balance dysbiosis: bacteria, parasites, yeast Toxic exposures (environmental, infectious, emotional) Excess of anything- food, stress, technology Replace restorative therapies: Restorative Sleep Supplemental repletion of mitochondrial cofactors Healing and anti-inflammatory foods Mind and body therapies (meditation, fasting, exercise) Hormones 72 9 4/7/20 Case Study #1 Hx: Mother of 3 children- vegan, moved into older home Tarrytown, statins x 5 years, recent infidelity in marriage (manages stress through over exercise). Sx: extreme fatigue, anxious, brain fog, muscle aches Labs: lead & serum candida +, MMA and homocysteine high, low CoQ10, low T3, TSH 6, thyroid US WNL. Surface testing in home + for mycotoxins Tx: Mold remediation and eradication of lead in old bathtub Adaptogenic herbs- ashwagandha, black cumin Methylated B vitamins, CoQ10, glutathione Mold detox with CSM and glutathione Limited exercise, Paleo diet, individual counseling, meditation 3 month F/U: labs normalized, energy 80% better, anxiety significantly reduced, working in couples counseling 73 Case Study #2 Hx: 6 year old boy with fatigue and developmental delay by 2 years, dx with ASD at 2.5 years, chronic OM and URIs, angry and oppositional mood Sx: Sleeps 13 hours a night and needs 1-2 naps per day, delayed speech, stimming, floppy tone, chronic constipation, refusal to eat anything that is not beige Labs: gluten sensitivity, organic acids showing mitochondrial insufficiencies, nutrient deficiencies in zinc, iron, carnitine, and B vitamins, candida cultured in stool Tx: GF diet, nutrient repletion with zinc, iron, B’s, and carnitine, Nystatin protocol x 6 weeks to remove fungal overgrowth in gut, Amantadine for glutamate modulation, 1 gram BID of magnesium threonate (brain and gut) 3 month F/U: No more naps are needed, wants to play more outside and for longer periods, mood is significantly improved, starting to try new foods, bowels are regular and soft, meeting goals in ABA faster than expected 74 COVID19 Integrative Response 75 10 4/7/20 COVID19 Proposed Prevention & Treatment Support Protocol 4/4/20 Prevention: (for adults and older children) • Vitamin A- 5,000IU daily • Vitamin C (Liposomal preferred)- 500mg twice daily • Vitamin D3- 5,000-10,000IU daily • Zinc- 40mg daily • Quercetin 400-800mg daily • L-glutathione 350-600mg daily • N-Acetyl- L-Cysteine (NAC)- 600mg daily • Melatonin 3-5mg at night For younGer children and very low risk: • Vitamin D- 2,500-5,000 IU daily • Vitamin C- 250-500mg daily • Zinc- 20-30mg daily Antiviral herbs to consider when exposure is hiGh: • Andrographis paniculate- 375mg twice daily • Black elderberry (Sambucas nigra)- 250mg twice daily Over the counter blends: • Immunitone Plus by Designs for Health- 2 caps twice daily (also contains anti-viral mushrooms) • Viracid by Ortho Molecular- 2 caps twice daily 76 Treatment for adults and hiGh-risk patients: Medications: 1. Azithromycin- 500mg daily- This would be 1 tablet (250mg) twice daily x 5 days 2. Hydroxychloroquine- 1 tablet twice daily x 10 days (caution in cardiac patients due to QT prolongation). Only use in higher risk patients, not children young and healthy. 3. Acetylcysteine- SOL (20%): 200 mg per mL (or inhaled glutathione 200mg per respule) combined with Albuterol (0.083%) nebs; can help prevent vasoconstriction and pulmonary fibrosis after illness is over, give 3-4 x daily and as needed. Hill Country Apothecary is compounding combo and ships all over Texas. Standard RX is feasible for acetylcysteine, but glutathione needs to be specialty compounded. Supplements: 1. Melatonin high dose (natural inflammasome) (5-10mg) 3x daily x 10 days 2. Magnesium Glycinate- 120mg given twice daily. This is very important especially for those taking hydroxychloroquine. 3. Vitamin C (ascorbic acid)- high dose 2-3 grams every hour while awake (averaging 8x day) x 1-2 days, then 2 grams 3x daily for the next 8 days. IV vitamin C preferred if accessible. 4. NEO 40- NOS (nitric oxide) inducers- 1 tablet 4x daily x 10 days 5. D Hist by Ortho Molecular- 2 caps 4x daily (quercetin and stinging nettles- for blood type A especially) x 10 days.
Load more

Recommended publications
  • N-Acyl-Dopamines: Novel Synthetic CB1 Cannabinoid-Receptor Ligands
    Biochem. J. (2000) 351, 817–824 (Printed in Great Britain) 817 N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Tiziana BISOGNO*, Dominique MELCK*, Mikhail Yu. BOBROV†, Natalia M. GRETSKAYA†, Vladimir V. BEZUGLOV†, Luciano DE PETROCELLIS‡ and Vincenzo DI MARZO*1 *Istituto per la Chimica di Molecole di Interesse Biologico, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy, †Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, R. A. S., 16/10 Miklukho-Maklaya Str., 117871 Moscow GSP7, Russia, and ‡Istituto di Cibernetica, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy We reported previously that synthetic amides of polyunsaturated selectivity for the anandamide transporter over FAAH. AA-DA fatty acids with bioactive amines can result in substances that (0.1–10 µM) did not displace D1 and D2 dopamine-receptor interact with proteins of the endogenous cannabinoid system high-affinity ligands from rat brain membranes, thus suggesting (ECS). Here we synthesized a series of N-acyl-dopamines that this compound has little affinity for these receptors. AA-DA (NADAs) and studied their effects on the anandamide membrane was more potent and efficacious than anandamide as a CB" transporter, the anandamide amidohydrolase (fatty acid amide agonist, as assessed by measuring the stimulatory effect on intra- hydrolase, FAAH) and the two cannabinoid receptor subtypes, cellular Ca#+ mobilization in undifferentiated N18TG2 neuro- CB" and CB#. NADAs competitively inhibited FAAH from blastoma cells. This effect of AA-DA was counteracted by the l µ N18TG2 cells (IC&! 19–100 M), as well as the binding of the CB" antagonist SR141716A.
    [Show full text]
  • Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: a Systematic Review of Human and Animal Evidence
    nutrients Review Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence Marco Colizzi 1,2,3,* , Riccardo Bortoletto 1, Rosalia Costa 4 and Leonardo Zoccante 1 1 Child and Adolescent Neuropsychiatry Unit, Maternal-Child Integrated Care Department, Integrated University Hospital of Verona, 37126 Verona, Italy; [email protected] (R.B.); [email protected] (L.Z.) 2 Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy 3 Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE5 8AF, UK 4 Community Mental Health Team, Department of Mental Health, ASST Mantova, 46100 Mantua, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-045-812-6832 Abstract: Autism spectrum disorder (ASD) pathophysiology is not completely understood; how- ever, altered inflammatory response and glutamate signaling have been reported, leading to the investigation of molecules targeting the immune-glutamatergic system in ASD treatment. Palmi- toylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective in controlling inflammation, depression, epilepsy, and pain, possibly through a neuro- Citation: Colizzi, M.; Bortoletto, R.; protective role against glutamate toxicity. Here, we systematically reviewed all human and animal Costa, R.; Zoccante, L. studies examining PEA and its biobehavioral correlates in ASD. Studies indicate altered serum/brain Palmitoylethanolamide and Its levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs) in ASD. Altered PEA Biobehavioral Correlates in Autism signaling response to social exposure and altered expression/activity of enzymes responsible for Spectrum Disorder: A Systematic the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator Review of Human and Animal α α Evidence.
    [Show full text]
  • Endocannabinoid System Dysregulation from Acetaminophen Use May Lead to Autism Spectrum Disorder: Could Cannabinoid Treatment Be Efficacious?
    molecules Review Endocannabinoid System Dysregulation from Acetaminophen Use May Lead to Autism Spectrum Disorder: Could Cannabinoid Treatment Be Efficacious? Stephen Schultz 1, Georgianna G. Gould 1, Nicola Antonucci 2, Anna Lisa Brigida 3 and Dario Siniscalco 4,* 1 Department of Cellular and Integrative Physiology, Center for Biomedical Neuroscience, University of Texas (UT) Health Science Center San Antonio, San Antonio, TX 78229, USA; [email protected] (S.S.); [email protected] (G.G.G.) 2 Biomedical Centre for Autism Research and Therapy, 70126 Bari, Italy; [email protected] 3 Department of Precision Medicine, University of Campania, 80138 Naples, Italy; [email protected] 4 Department of Experimental Medicine, University of Campania, 80138 Naples, Italy * Correspondence: [email protected] Abstract: Persistent deficits in social communication and interaction, and restricted, repetitive pat- terns of behavior, interests or activities, are the core items characterizing autism spectrum disorder (ASD). Strong inflammation states have been reported to be associated with ASD. The endocannabi- noid system (ECS) may be involved in ASD pathophysiology. This complex network of lipid signal- ing pathways comprises arachidonic acid and 2-arachidonoyl glycerol-derived compounds, their G-protein-coupled receptors (cannabinoid receptors CB1 and CB2) and the associated enzymes. Alter- Citation: Schultz, S.; Gould, G.G.; ations of the ECS have been reported in both the brain and the immune system of ASD subjects. ASD Antonucci, N.; Brigida, A.L.; Siniscalco, D. Endocannabinoid children show low EC tone as indicated by low blood levels of endocannabinoids. Acetaminophen System Dysregulation from use has been reported to be associated with an increased risk of ASD.
    [Show full text]
  • Grunddokument 2
    The cellular processing of the endocannabinoid anandamide and its pharmacological manipulation Lina Thors Department of Pharmacology and Clinical Neuroscience SE-901 87 Umeå, Sweden Umeå 2009 1 Copyright©Lina Thors ISBN: 978-91-7264-732-9 ISSN: 0346-6612 Printed by: Print & Media Umeå, Sweden 2009 2 Abstract Anandamide (arachidonoyl ethanolamide, AEA) and 2-arachidonoyl glycerol (2-AG) exert most of their actions by binding to cannabinoid receptors. The effects of the endocannabinoids are short-lived due to rapid cellular accumulation and metabolism, for AEA, primarily by the enzymes fatty acid amide hydrolase (FAAH). This has led to the hypothesis that by inhibition of the cellular processing of AEA, beneficial effects in conditions such as pain and inflammation can be enhanced. The overall aim of the present thesis has been to examine the mechanisms involved in the cellular processing of AEA and how they can be influenced pharmacologically by both synthetic natural compounds. Liposomes, artificial membranes, were used in paper I to study the membrane retention of AEA. The AEA retention mimicked the early properties of AEA accumulation, such as temperature- dependency and saturability. In paper II, FAAH was blocked by a selective inhibitor, URB597, and reduced the accumulation of AEA into RBL2H3 basophilic leukaemia cells by approximately half. Treating intact cells with the tyrosine kinase inhibitor genistein, an isoflavone found in soy plants and known to disrupt caveolae-related endocytosis, reduced the AEA accumulation by half, but in combination with URB597 no further decrease was seen. Further on, the effects of genistein upon uptake were secondary to inhibition of FAAH.
    [Show full text]
  • SYNTHESIS of 3-HETEROCYCLE PHENYL N-ALKYL CARBAMATES and THEIR ACTIVITY AS FAAH INHIBITORS Doctoral Dissertation
    TKK Dissertations 203 Espoo 2009 SYNTHESIS OF 3-HETEROCYCLE PHENYL N-ALKYL CARBAMATES AND THEIR ACTIVITY AS FAAH INHIBITORS Doctoral Dissertation Mikko Myllymäki Helsinki University of Technology Faculty of Chemistry and Materials Sciences Department of Chemistry TKK Dissertations 203 Espoo 2009 SYNTHESIS OF 3-HETEROCYCLE PHENYL N-ALKYL CARBAMATES AND THEIR ACTIVITY AS FAAH INHIBITORS Doctoral Dissertation Mikko Myllymäki Dissertation for the degree of Doctor of Philosophy to be presented with due permission of the Faculty of Chemistry and Materials Sciences for public examination and debate in Auditorium KE2 (Komppa Auditorium) at Helsinki University of Technology (Espoo, Finland) on the 19th of December, 2009, at 12 noon. Helsinki University of Technology Faculty of Chemistry and Materials Sciences Department of Chemistry Teknillinen korkeakoulu Kemian ja materiaalitieteiden tiedekunta Kemian laitos Distribution: Helsinki University of Technology Faculty of Chemistry and Materials Sciences Department of Chemistry P.O. Box 6100 (Kemistintie 1) FI - 02015 TKK FINLAND URL: http://chemistry.tkk.fi/ Tel. +358-9-470 22527 Fax +358-9-470 22538 E-mail: [email protected] © 2009 Mikko Myllymäki ISBN 978-952-248-240-2 ISBN 978-952-248-241-9 (PDF) ISSN 1795-2239 ISSN 1795-4584 (PDF) URL: http://lib.tkk.fi/Diss/2009/isbn9789522482419/ TKK-DISS-2686 Multiprint Oy Espoo 2009 3 AB HELSINKI UNIVERSITY OF TECHNOLOGY ABSTRACT OF DOCTORAL DISSERTATION P.O. BOX 1000, FI-02015 TKK http://www.tkk.fi Author Mikko Juhani Myllymäki Name of the dissertation
    [Show full text]
  • The Use of Cannabinoids in Animals and Therapeutic Implications for Veterinary Medicine: a Review
    Veterinarni Medicina, 61, 2016 (3): 111–122 Review Article doi: 10.17221/8762-VETMED The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review L. Landa1, A. Sulcova2, P. Gbelec3 1Faculty of Medicine, Masaryk University, Brno, Czech Republic 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic 3Veterinary Hospital and Ambulance AA Vet, Prague, Czech Republic ABSTRACT: Cannabinoids/medical marijuana and their possible therapeutic use have received increased atten- tion in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veteri- nary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific lit- erature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary
    [Show full text]
  • Can Celecoxib Enhance Palmitoylethanolamide's Effect In
    Journal of Translational Science Case Series ISSN: 2059-268X Can Celecoxib enhance Palmitoylethanolamide’s effect in the treatment of Temporo-mandibular arthralgia in osteoarthritis patients? Marini I1*, Cavallaro M1, Bartolucci ML1, Alessandri-Bonetti A2, Gatto MR1, Cordaro M2 and Checchi L1 1Department of Biomedical Sciences, “Alma Mater Studiorum” University of Bologna, Bologna, 40126, Italy 2School of Dentistry, Catholic University of Sacred Heart, Rome, 00168, Italy Abstract Osteoarthritis (OA) is a degenerative disease of joints commonly associated with arthralgia when affecting Temporo-Mandibular Joints (TMJ). Pain management generally consists of nonsteroidal anti-inflammatory drug (NSAIDs), but due to the important side effects related to its use, Palmitoylethanolamide (PEA) has been taken into consideration. PEA acts as an endogenous agent with anti-inflammatory effect, it also has an analgesic effect starting from the fourth day of treatment. A case series analysis was retrospectively conducted in order to assess if the association of PEA and Celecoxib, a cyclooxygenase-2 inhibitor, provides a quicker reduction of pain. 12 patients were treated with this association for 4 days and with PEA alone for the following 10 days. Maximum mouth opening was also recorded. A progressive pain decrease was clearly noticeable over time allowing to reach a significant reduction after 4 days and no significant pain intensity at the end of the treatment (p = 0.0001). Maximum mouth opening also improved (p=0,0093). This data suggest that the association of PEA and Celecoxib is effective in TMJ-OA treatment without showing side effects. It should be considered as a safe and valid alternative to NSAIDs.
    [Show full text]
  • Review Article Palmitoylethanolamide: a Natural Body-Own Anti-Inflammatory Agent, Effective and Safe Against Influenza and Common Cold
    Hindawi Publishing Corporation International Journal of Inflammation Volume 2013, Article ID 151028, 8 pages http://dx.doi.org/10.1155/2013/151028 Review Article Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold J. M. Keppel Hesselink,1 Tineke de Boer,2 and Renger F. Witkamp3 1 Faculty of Medicine, University Witten/Herdecke, Alfred-Herrhausen-Straße 50, 58448 Witten, Germany 2 DepartmentofResearchandDevelopment,InstituteforNeuropathicPain,Spoorlaan2a,3735MVBoschenDuin,TheNetherlands 3 Division of Human Nutrition (Bode 62), Wageningen University, P.O. Box 8129, 6700 EV Wageningen, The Netherlands Correspondence should be addressed to J. M. Keppel Hesselink; [email protected] Received 3 April 2013; Revised 9 June 2013; Accepted 10 June 2013 Academic Editor: Juan Carlos Kaski Copyright © 2013 J. M. Keppel Hesselink et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Palmitoylethanolamide (PEA) is a food component known since 1957. PEA is synthesized and metabolized in animal cells via a number of enzymes and exerts a multitude of physiological functions related to metabolic homeostasis. Research on PEA has been conducted for more than 50 years, and over 350 papers are referenced in PubMed describing the physiological properties of this endogenous modulator and its pharmacological and therapeutical profile. The major focus of PEA research, since the work of the Nobel laureate Levi-Montalcini in 1993, has been neuropathic pain states and mast cell related disorders. However, it is less known that 6 clinical trials in a total of nearly 4000 people were performed and published last century, specifically studying PEA as a therapy for influenza and the common cold.
    [Show full text]
  • First Evidence of the Conversion of Paracetamol to AM404 in Human
    Journal of Pain Research Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH First evidence of the conversion of paracetamol WR$0LQKXPDQFHUHEURVSLQDOÁXLG This article was published in the following Dove Press journal: Journal of Pain Research Chhaya V Sharma,1 Jamie H Abstract: Paracetamol is arguably the most commonly used analgesic and antipyretic drug Long,2 Seema Shah,1 Junia worldwide, however its mechanism of action is still not fully established. It has been shown to Rahman,1 David Perrett,3 exert effects through multiple pathways, some actions suggested to be mediated via N-arachi- Samir S Ayoub,4 Vivek donoylphenolamine (AM404). AM404, formed through conjugation of paracetamol-derived Mehta1 p-aminophenol with arachidonic acid in the brain, is an activator of the capsaicin receptor, TRPV1, and inhibits the reuptake of the endocannabinoid, anandamide, into postsynaptic neurons, 1Pain & Anaesthesia Research Centre, as well as inhibiting synthesis of PGE by COX-2. However, the presence of AM404 in the cen- St Bartholomew’s and The Royal 2 London Hospitals, Barts Health NHS tral nervous system following administration of paracetamol has not yet been demonstrated in Trust, London, UK; 2Barts & The humans. Cerebrospinal fluid (CSF) and blood were collected from 26 adult male patients between London School of Medicine, Queen Mary University of London, London, 10 and 211 minutes following intravenous administration of 1 g of paracetamol. Paracetamol UK; 3BioAnalytical Science, Barts & was measured by high-performance liquid chromatography with UV detection. AM404 was The London School of Medicine, measured by liquid chromatography-tandem mass spectrometry.
    [Show full text]
  • Palmitoylethanolamide: a Nutritional Approach to Keep Neuroinflammation Within Physiological Boundaries—A Systematic Review
    International Journal of Molecular Sciences Review Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries—A Systematic Review Stefania Petrosino 1,2,* and Aniello Schiano Moriello 1,2 1 Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Napoli, Italy; [email protected] 2 Epitech Group SpA, Via Einaudi 13, 35030 Padova, Italy * Correspondence: [email protected] Received: 30 October 2020; Accepted: 9 December 2020; Published: 15 December 2020 Abstract: Neuroinflammation is a physiological response aimed at maintaining the homodynamic balance and providing the body with the fundamental resource of adaptation to endogenous and exogenous stimuli. Although the response is initiated with protective purposes, the effect may be detrimental when not regulated. The physiological control of neuroinflammation is mainly achieved via regulatory mechanisms performed by particular cells of the immune system intimately associated with or within the nervous system and named “non-neuronal cells.” In particular, mast cells (within the central nervous system and in the periphery) and microglia (at spinal and supraspinal level) are involved in this control, through a close functional relationship between them and neurons (either centrally, spinal, or peripherally located). Accordingly, neuroinflammation becomes a worsening factor in many disorders whenever the non-neuronal cell supervision is inadequate. It has been shown that the regulation of non-neuronal cells—and therefore the control of neuroinflammation—depends on the local “on demand” synthesis of the endogenous lipid amide Palmitoylethanolamide and related endocannabinoids. When the balance between synthesis and degradation of this bioactive lipid mediator is disrupted in favor of reduced synthesis and/or increased degradation, the behavior of non-neuronal cells may not be appropriately regulated and neuroinflammation exceeds the physiological boundaries.
    [Show full text]
  • Therapeutic Efficacy of Palmitoylethanolamide And
    nutrients Communication Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets 1, 1, 1 1,2, Alessio Filippo Peritore y, Rosalba Siracusa y, Rosalia Crupi and Salvatore Cuzzocrea * 1 Department of Chemical Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’Alcontres 31, 98166 Messina, Italy 2 Department of Pharmacological and Physiological Sciences, Saint Louis University School of Medicine, St. Louis, MO 63104, USA * Correspondence: [email protected] The first two authors contributed equally to this study. y Received: 15 July 2019; Accepted: 5 September 2019; Published: 11 September 2019 Abstract: The use of a complete nutritional approach seems increasingly promising to combat chronic inflammation. The choice of healthy sources of carbohydrates, fats, and proteins, associated with regular physical activity and avoidance of smoking is essential to fight the war against chronic diseases. At the base of the analgesic, anti-inflammatory, or antioxidant action of the diets, there are numerous molecules, among which some of a lipidic nature very active in the inflammatory pathway. One class of molecules found in diets with anti-inflammatory actions are ALIAmides. Among all, one is particularly known for its ability to counteract the inflammatory cascade, the Palmitoylethanolamide (PEA). PEA is a molecular that is present in nature, in numerous foods, and is endogenously produced by our body, which acts as a balancer of inflammatory processes, also known as endocannabionoid-like. PEA is often used in the treatment of both acute and chronic inflammatory pathologies, either alone or in association with other molecules with properties, such as antioxidants or analgesics.
    [Show full text]
  • Fatty Acid Amide Hydrolase: an Emerging Therapeutic Target in the Endocannabinoid System Benjamin F Cravatt and Aron H Lichtman
    469 Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system Benjamin F Cravattà and Aron H Lichtman The medicinal properties of exogenous cannabinoids have been glycerol (2-AG) as a second endocannabinoid [5,6] has recognized for centuries and can largely be attributed to the fortified the hypothesis that cannabinoid (CB) receptors activation in the nervous system of a single G-protein-coupled are part of the sub-class of GPCRs that recognize lipids as receptor, CB1. However, the beneficial properties of their natural ligands. Consistent with this notion, based on cannabinoids, which include relief of pain and spasticity, are primary structural alignment of the GPCR superfamily, counterbalanced by adverse effects such as cognitive and motor CB receptors are most homologous to the edg receptors, dysfunction. The recent discoveries of anandamide, a natural which also bind endogenous lipids such as lysophospha- lipid ligand for CB1, and an enzyme, fatty acid amide hydrolase tidic acid and sphingosine 1-phosphate [7]. (FAAH), that terminates anandamide signaling have inspired pharmacological strategies to augment endogenous The identification of anandamide and 2-AG as endocan- cannabinoid (‘endocannabinoid’) activity with FAAH inhibitors, nabinoids has stimulated efforts to understand the which might exhibit superior selectivity in their elicited behavioral mechanisms for their biosynthesis and inactivation. Both effects compared with direct CB1 agonists. anandamide and 2-AG belong to large classes of natural
    [Show full text]